Resistance to PARP-Inhibitors in Cancer Therapy
| Autor: | Émilie Pouliot, Mihaela Robu, Alicia Montoni, Girish M. Shah |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Combination therapy
DNA repair Mini Review potentiation of anti-cancer therapy Poly ADP ribose polymerase Cancer therapy Synthetic lethality Inhibitors of PARP 03 medical and health sciences 0302 clinical medicine Poly(ADP-ribose) polymerase (PARP) Medicine Pharmacology (medical) Homologous Recombination 030304 developmental biology Pharmacology Genetics 0303 health sciences business.industry lcsh:RM1-950 resistance to PARP-inhibitors poly(ADP-ribose) polymerase synthetic lethality 3. Good health Clinical trial lcsh:Therapeutics. Pharmacology 030220 oncology & carcinogenesis Cancer cell PARP-inhibitors Cancer research DNA damage business |
| Zdroj: | Frontiers in Pharmacology Frontiers in Pharmacology, Vol 4 (2013) |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2013.00018 |
| Popis: | The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers. Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase with time, but resistance of cancer cells to PARPi is also beginning to be observed. Here we review different known and potential mechanisms by which: (i) PARPi kill cancer cells; and (ii) cancer cells develop resistance to PARPi. Understanding the lethality caused by PARPi and the countermeasures deployed by cancers cells to survive PARPi will help us rationalize the use of this new class of drugs in cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|